Republic of the Philippines

CAVITE STATE UNIVERSITY

(CvSU)
Don Severino Delas Alas Campus
Indang, Cavite
(046) 4150-010 / 4150-011 (046) 4150-012

DRUG STUDY
NAME OF PATIENT: JB DATE OF ADMISSION: AUGUST 6, 2014
AGE: 42 YEARS OLD DIAGNOSIS: POST CHOLELITHIASIS
SEX: MALE
Drug Features
Mechanism of
Action
Indication

Contraindication

Effects Nursing Responsibilities
Generic Name:
MEFENAMIC ACID
Brand Name:

Classification:
NONSTEROIDAL
ANTI-
INFLAMMATORY
AGENTS
Sub Classification:
NONE
Dosage:
500 mg
Route:
PO once in diet
Frequency:
TID
Form:
Capsule
Color:
Blue green and
cream white
capsule color
Analgesics and
anti-inflammatory
effects: inhibition
of prostaglandin
synthesis.
Antipyretic
effects:
vasodilation and
inhibition of
prostaglandin
synthesis in the
CNS.
COX-2 inhibitors
may cause less GI
bleeding.
Control mild to
moderate pain, fever,
and various
inflammatory
conditions, such as
rheumatoid arthritis
and osteoarthritis.
Hypersensitivity to
aspirin is a
contraindication.
Use caustiously in
patients with a
history of bleeding
disorders, GI
bleeding, and severe
hepatic, renal, or
cardiovascular
disease.

Side Effects & Adverse
Effects:
GI disturbances, peptic
ulceration, and GI
bleeding, headache,
drowsiness, dizziness,
nervousness, visual
disturbances, renal
failure,
glomerulonephritis,
papillary necrosis
Check for Doctors order
Observe 10Rs of the patient in medicine
administration

Assessment:
Patients who have asthma, allergies, and
nasal polyps or who are allergic to
tartrazine are at an increased risk for
developing hypersensitivity
reactions.
Pain: Assess pain and limitation of
movement; note type, location, and
intensity before and at the peak (see
Time/Action Profile) after
administration.
Fever: Assess fever and note associated
signs (diaphoresis, tachycardia,
malaise, chills).
Lab Test Considerations: Monitor hepatic
function before antirheumatic
therapy and if symptoms of
hepatotoxicity occur; more likely in
patients, especially children, with
rheumatic fever, systemic lupus
erythematosus, juvenile arthritis, or
pre-existing hepatic disease. May
cause serum AST, ALT, and
alkaline phosphatase, especially


when plasma concentrations exceed
25 mg/100 mL. May return to
normal despite continued use or
dose reduction. If severe
abnormalities or active liver disease
occurs, discontinue and use with
caution in future.
May alter results of serum uric acid,
urine vanillylmandelic acid (VMA),
protirelin-induced thyroid-
stimulating hormone (TSH), urine
hydroxyindoleacetic acid (5-HIAA)
determinations, and radionuclide
thyroid imaging.
Prolongs bleeding time for 47 days and,
in large doses, may cause prolonged
prothrombin time. Monitor
hematocrit periodically in prolonged
high-dose therapy to assess for GI
blood loss .
Toxicity and Overdose: Monitor for the
onset of tinnitus, headache,
hyperventilation, agitation, mental
confusion, lethargy, diarrhea, and
sweating. If these symptoms appear,
withhold medication and notify physician
or other health care professional
immediately.
Patient/Family Teaching
Instruct patient to take with a full glass
of water and to remain in an upright
position for 1530 min after
administration.
Advise patient to report tinnitus; unusual
bleeding of gums; bruising; black, tarry
stools; or fever lasting longer than 3
days.


Caution patient to avoid concurrent use
of alcohol with this medication to
minimize possible gastric irritation; 3 or
more glasses of alcohol per day may
increase the risk of GI bleeding. Caution
patient to avoid taking concurrently with
acetaminophen or NSAIDs for more than
a few days, unless directed by health
care professional to prevent analgesic
nephropathy.
Tablets with an acetic (vinegar-like) odor
should be discarded.
Advise patients on long-term therapy to
inform health care professional of
medication regimen before surgery.